Investors who purchased the Company’s securities between July 6, 2020 and March 31, 2021, inclusive (the ”Class Period”), are encouraged to contact the firm before June 18, 2021.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at email@example.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Emergent BioSolution’s Baltimore facility had a pattern of manufacturing problems resulting in an increased likelihood of product contamination. The company suffered from a string of FDA citations due to the poor quality of its Baltimore operations. The Company was forced to discard the equivalent of millions of COVID-19 vaccine doses after the plant deviated from standard procedures. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Emergent BioSolutions, investors suffered damages.
The Schall Law Firm
Brian Schall, Esq.,